{"commentary":{"count":26,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":12,"youtube":11,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05687266\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"AVANZAR","nct_id":"NCT05687266","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=avanzar-nct05687266. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"AVANZAR","arms":[{"description":"Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 1120 mg durvalumab plus carboplatin area under the curve \\[AUC\\] 5 mg/mL/minute.","label":"Dato-DXd + Durvalumab + Carboplatin","type":"EXPERIMENTAL"},{"description":"Non-squamous NSCLC participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m2 pemetrexed plus either AUC 5 mg/mL/minute carboplatin or 75 mg/m2 cisplatin.\n\nSquamous NSCLC participants will be randomized to receive 200 mg of pembrolizumab plus 200 mg/m2 paclitaxel plus AUC 5 or 6 mg/mL/minute carboplatin.","label":"Histologic-specific therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"conditions":["NSCLC"],"enrollment":{"count":1350,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Datopotamab deruxtecan","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population","timeFrame":"Approximately 3 years"},{"measure":"Overall Survival (OS) in the non-squamous TROP2 biomarker positive population","timeFrame":"Approximately 5 years"},{"measure":"PFS by BICR in the non-squamous population","timeFrame":"Approximately 3 years"},{"measure":"OS in the non-squamous population","timeFrame":"Approximately 5 years"}],"references":[],"start_date":{"date":"2022-12-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","url":"https://clinicaltrials.gov/study/NCT05687266"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/avanzar-nct05687266"}